INmune Bio Inc (NASDAQ:INMB) Chairman Raymond Joseph Tesi Purchases 11,100 Shares

INmune Bio Inc (NASDAQ:INMB) Chairman Raymond Joseph Tesi acquired 11,100 shares of the stock in a transaction on Thursday, May 2nd. The shares were bought at an average price of $9.90 per share, for a total transaction of $109,890.00. The purchase was disclosed in a document filed with the SEC, which is accessible through this link.

INmune Bio stock traded down $0.15 during mid-day trading on Friday, reaching $10.25. 7,677 shares of the company were exchanged, compared to its average volume of 17,999. INmune Bio Inc has a 12 month low of $7.00 and a 12 month high of $11.50.

Separately, Maxim Group initiated coverage on INmune Bio in a research note on Tuesday, March 19th. They set a “buy” rating and a $13.00 price objective on the stock.

TRADEMARK VIOLATION NOTICE: “INmune Bio Inc (NASDAQ:INMB) Chairman Raymond Joseph Tesi Purchases 11,100 Shares” was published by Rockland Register and is the property of of Rockland Register. If you are reading this piece on another domain, it was copied illegally and republished in violation of US and international trademark and copyright legislation. The legal version of this piece can be read at https://rocklandregister.com/2019/05/31/insider-buying-inmune-bio-inc-inmb-chairman-buys-109890-00-in-stock.html.

About INmune Bio

INmune Bio Inc, a clinical-stage immunotherapy company, focuses on engineering and harnessing the innate immune system to treat the patient's cancer. The company intends to develop and commercialize product candidates to treat diseases comprising hematologic malignancies and solid tumors. Its development programs include INKmune, which focuses on treating women with relapse refractory ovarian carcinoma; and INB03 that treats patients with advanced cancers with elevated biomarkers of inflammation, including elevated levels of myeloid derived suppressor cells in their blood.

See Also: What is Green Investing?

Receive News & Ratings for INmune Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for INmune Bio and related companies with MarketBeat.com's FREE daily email newsletter.